
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
AUSTIN, Texas, May 1, 2025 (PR Newswire) —Rein Therapeutics (“Rein”) (NASDAQ: RNTX), a biopharmaceutical

AUSTIN, Texas, May 1, 2025 (PR Newswire) —Rein Therapeutics (“Rein”) (NASDAQ: RNTX), a biopharmaceutical

9 October 2024 The Royal Swedish Academy of Sciences has decided to award the
AI is an end-to-end solution for small molecule drug discovery combining AI and

“Deep Learning-Predicted Dihydroartemisinin Rescues Osteoporosis by Maintaining Mesenchymal Stem Cell Stemness through Activating Histone

“ChatGPT Chemistry Assistant for Text Mining and the Prediction of MOF Synthesis” Journal of